Vancouver, British Columbia--(Newsfile Corp. - June 25, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing innovative solutions for the ...
Designation Facilitates and Expedites Development of Drugs for Patients with Serious Unmet Medical Needs Enrollment Progressing in NVG-291 Phase 1b/2a Clinical Trial, with Initial Cohort Data Expected ...
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Nuvig Therapeutics, Inc. (“Nuvig” or the “Company”), a privately held biotechnology company developing novel immunomodulatory therapeutics for patients with ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results